Olema appoints Prakash Raman to board as it advances oncology pipeline
Olema Pharmaceuticals appointed Prakash Raman, Ph.D., to its board of directors. The company said the oncology deal veteran joins as Olema advances palazestrant and OP-3136 while remaining loss-making.
Olema Pharmaceuticals has appointed Prakash Raman, Ph.D., to its Board of Directors. The company said Dr. Raman is an industry veteran with extensive executive and business development experience at large biopharmaceutical companies. The board change adds a member with a long track record in oncology partnerships and acquisitions.
Olema focuses on oncology drug development and is advancing palazestrant and OP-3136. Dr. Raman has led business development at Novartis, helped shape acquisitions such as Advanced Accelerator Applications and Endocyte, and now runs InduPro Therapeutics.
The company is still an early-stage, loss-making business. Olema is unprofitable and has reported a net loss of US$162.451 million, while generating less than US$1 million in revenue.
The appointment adds board-level experience in immuno-oncology and small-molecule development as Olema progresses its pipeline. The move does not change Olema’s clinical or financial profile on its own, but it does adjust the mix of voices influencing long-term direction.